Improved AAV tropism is essential for gene therapy to reach its full potential. New capsid engineering techniques are taking on this challenge. Clinical translation of gene therapies has a history ...

Code and documentation supporting "Targeting AAV vectors to the CNS via de novo engineered capsid-receptor interactions", including data, SVAE-based variant generation method, and figure-generation ...

To flip the ratio and bias an AAV away from toxic hotspots and towards a target organ or cell, researchers like Deverman, Gradinaru, and Davidson have developed capsid engineering strategies to put ...

With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

Two fundamental aspects of AAV research are the accurate quantification of AAV capsid titters and the detection of pre-existing antibodies against AAV. These measurements are essential for ensuring ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

Capsid engineering efforts aim to reroute in vivo AAV biodistribution away from the liver toward disease-relevant peripheral ...

In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit. The Vericheck ddPCR Empty-Full Capsid ...

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.